The DOI matches its Crossref record.
Vascular and Cellular Targeting for Photodynamic Therapy
Abstract
Photodynamic therapy (PDT) involves the combination of photosensitizers (PS) with light as a treatment, and has been an established medical practice for about 10 years. Current primary applications of PDT are age-related macular degeneration (AMD) and several types of cancer and precancer. Tumor vasculature and parenchyma cells are both potential targets of PDT damage. The preference of vascular versus cellular targeting is highly dependent upon the relative distribution of photosensitizers in each compartment, which is governed by the photosensitizer pharmacokinetic properties and can be effectively manipulated by the photosensitizer drug administration and light illumination interval (drug-light interval) during PDT treatment, or by the modification of photosensitizer molecular structure. PDT using shorter PS-light intervals mainly targets tumor vasculature by confining photosensitizer localization within blood vessels, whereas if the sensitizer has a reasonably long pharmacokinetic lifetime, then PDT at longer PS-light intervals can induce more tumor cellular damage, because the photosensitizer has then distributed into the tumor cellular compartment. This passive targeting mechanism is regulated by the innate photosensitizer physicochemical properties. In addition to the passive targeting approach, active targeting of various tumor endothelial and cellular markers has been studied extensively. The tumor cellular markers that have been explored for active photodynamic targeting are mainly tumor surface markers, including growth factor receptors, low-density lipoprotein (LDL) receptors, transferrin receptors, folic acid receptors, glucose transporters, integrin receptors, and insulin receptors. In addition to tumor surface proteins, nuclear receptors are targeted, as well. A limited number of studies have been performed to actively target tumor endothelial markers (ED-B domain of fibronectin, VEGF receptor-2, and neuropilin-1). Intracellular targeting is a challenge due to the difficulty in achieving sufficient penetration into the target cell, but significant progress has been made in this area. In this review, we summarize current studies of vascular and cellular targeting of PDT after more than 30 years of intensive efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nanoparticles in Photodynamic Therapy
Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,980
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., Pogue, B. W., & Hasan, T. (2010) · Chemical Reviews · doi:10.1021/cr900300p · Cited by 2,324
Self-citationO’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Photodynamic Therapy in Dentistry
Konopka, K., & Goslinski, T. (2007) · Journal of Dental Research · doi:10.1177/154405910708600803 · Cited by 854
Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy
Awuah, S. G., & You, Y. (2012) · RSC Advances · doi:10.1039/c2ra21404k · Cited by 632
Josefsen, L. B., & Boyle, R. W. (2012) · Theranostics · doi:10.7150/thno.4571 · Cited by 575
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Mallidi, S., Anbil, S., Bulin, A.-L., Obaid, G., Ichikawa, M., & Hasan, T. (2016) · Theranostics · doi:10.7150/thno.16183 · Cited by 449
Self-citationCell death in photodynamic therapy: From oxidative stress to anti-tumor immunity
Donohoe, C., Senge, M. O., Arnaut, L. G., & Gomes-da-Silva, L. C. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.07.003 · Cited by 442
Photodynamic Therapy for Treatment of Solid Tumors — Potential and Technical Challenges
Huang, Z., Xu, H., Meyers, A. D., Musani, A. I., Wang, L., Tagg, R., Barqawi, A. B., & Chen, Y. K. (2008) · Technology in Cancer Research & Treatment · doi:10.1177/153303460800700405 · Cited by 337
Ohulchanskyy, T. Y., Roy, I., Goswami, L. N., Chen, Y., Bergey, E. J., Pandey, R. K., Oseroff, A. R., & Prasad, P. N. (2007) · Nano Letters · doi:10.1021/nl0714637 · Cited by 329
Recent Progress in Near Infrared Light Triggered Photodynamic Therapy
Deng, K., Li, C., Huang, S., Xing, B., Jin, D., Zeng, Q., Hou, Z., & Lin, J. (2017) · Small · doi:10.1002/smll.201702299 · Cited by 324
Milestones in the development of photodynamic therapy and fluorescence diagnosis
Juzeniene, A., Peng, Q., & Moan, J. (2007) · Photochemical & Photobiological Sciences · doi:10.1039/b705461k · Cited by 273
Features of third generation photosensitizers used in anticancer photodynamic therapy: Review
Mfouo-Tynga, I. S., Dias, L. D., Inada, N. M., & Kurachi, C. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2020.102091 · Cited by 260
Rodriguez, L., de Bruijn, H. S., Di Venosa, G., Mamone, L., Robinson, D. J., Juarranz, A., Batlle, A., & Casas, A. (2009) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2009.07.001 · Cited by 37
Bian, S., Zheng, X., Liu, W., Li, J., Gao, Z., Ren, H., Zhang, W., Lee, C.-S., & Wang, P. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122130 · Cited by 29
Metadata
- Authors
- Chen, B., Pogue, B. W., Hoopes, P. J., & Hasan, T.
- Venue
- Critical Reviews™ in Eukaryotic Gene Expression
- Publisher
- Begell House
- Published
- 2006
- Volume
- 16
- Issue
- 4
- Pages
- 279-306
- ISSN
- 1045-4403 (ISSN-L)
- OpenAlex
- W2034008755
- Cited by
- 233
- References
- 0
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.